Dario Signs Four New Employer Contracts Across Full Product Suite
Dario Signs Four New Employer Contracts Across Full Product Suite
Company expects to reach an estimated total of 25 new client signings in 2024, representing an approximate 35% growth in client base compared to 2023
公司预计在2024年将签约25家新客户,比2023年增长约35%,代表着客户基数的增长
NEW YORK, Nov. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of four contracts with self-insured employers that are expected to go live in the first quarter of 2025.
纽约,2024年11月21日,新闻资讯/ - DarioHealth Corp.(纳斯达克:DRIO)(“Dario”或“公司”),是全球数字医疗领域的领导者,今天宣布与四家自保雇主签约,预计将于2025年第一季度启动
Dario has added four new employer contracts to the 2025 book of business, continuing the business momentum in the Business-to-Business-to-Consumer (B2B2C) channel and securing recurring revenue from these accounts starting in the first quarter of 2025. The contracts span across the full suite of the Dario platform, with no one opting for a single condition, showing evidence of the value of a multi-condition offering.
Dario已向2025年业务成交额新增了四份雇主合约,继续在Business-to-Business-to-Consumer(B2B2C)渠道上保持业务势头,并从2025年第一季度开始为这些账户提供持续营收。 合同涵盖Dario平台的全部套件,没有人选择单一条件,显示出多条件提供的价值证据
"We believe that employer contracts are a solid contributor to near-term growth for Dario. Each one adds recurring revenue, aids gross margin growth, and spreads our reach across new populations of users, adding to our ever-growing data pool. Including these four new employers, we expect to reach an estimated total of 25 new client signings in 2024, which are expected to be implemented and secured for revenue growth in 2025. This represents an approximate 35% growth in our client base compared to 2023, a milestone that we believe serves as a core indicator of our profitability timeline," said Steven Nelson, Chief Commercial Officer at Dario.
“我们相信雇主合同对Dario的近期增长是一个稳定的贡献者。每一个合同都增加了循环营收,促进了毛利率的增长,并扩大了我们覆盖的用户群,为我们不断增长的数据池增加了内容。包括这四家新雇主,在2024年我们预计将签署25份新客户合约,预计将在2025年为营收增长实施和保障。 这代表了与2023年相比我们客户基数约35%的增长,我们相信这是我们盈利时间表的核心指标”,Dario的首席商务官Steven Nelson表示。
About DarioHealth Corp.
关于dariohealth公司。
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DarioHealth Corp.(纳斯达克股票代码:DRIO)是一家领先的数字健康公司,通过以用户为中心的多慢性疾病数字治疗平台改变了人们管理慢性疾病的方式。Dario的平台和解决方案套件通过数据分析和一对一辅导为糖尿病、高血压、体重管理、肌肉骨骼疼痛和行为健康提供个性化和动态的干预措施。
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario的以用户为中心的平台为人们提供持续和定制的健康护理服务,打破传统的病情发作式医疗模式。这种方法赋予人们全面调整其生活方式以实现可持续行为改变的能力,推动用户满意度、留存率和结果的提高,使正确的事情变得易如反掌。
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit .
Dario将其备受用户好评的解决方案全球提供给健康计划和其他支付方、自保雇主、医疗服务提供者和消费者。欲了解更多关于Dario及其数字健康解决方案的信息,请访问 .
Cautionary Note Regarding Forward-Looking Statements
关于前瞻性声明的警告
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected timing of the launch of the four contracts, that the new contracts will continue business momentum in the B2B2C channel and secure recurring revenue from these accounts starting January 1st, 2025, that the employer contracts will contribute to the to near-term growth of the Company, aid gross margin growth, and spread its reach across new populations of users, adding to its data pool, that the Company expects to reach an estimated total of 25 new client signings by the end of 2024 to be implemented and secured for revenue growth in 2025, and the belief that the increase in contracts serves as a core indicator of its profitability timeline . Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
此新闻稿及DarioHealth Corp.的代表和合作伙伴的声明可能包含根据1995年《私人证券诉讼改革法案》规定的前瞻性声明。 非历史事实的陈述可能被认为是前瞻性声明。 例如,当公司谈论预计推出四项合同的时间、新合同将继续B2B2C渠道的业务势头并从2025年1月1日开始确保这些账户的循环收入、雇主合同将有助于公司近期增长、帮助毛利率增长、扩大用户群体规模并增加数据池时,该公司在本新闻稿中使用前瞻性声明,并预计到2024年底将达到约25个新客户签约总数,以便在2025年为营收增长实施和确认,并且公司认为合同数量的增加是其盈利时间表的主要指标。 在不限制前述内容的普遍性的情况下,例如“计划”、“项目”、“潜力”、“寻求”、“可能”、“将”、“期望”、“相信”、“预期”、“意图”、“可能”、“估计”或“持续”等词语旨在识别前瞻性声明。 读者应注意,某些重要因素可能会影响公司的实际结果,并可能导致这些结果与可能在本新闻稿中作出的任何前瞻性声明存在实质性差异。 可能影响公司结果的因素包括但不限于,监管批准、产品需求、市场接受程度、竞争产品和价格的影响、产品开发、商业化或技术困难、谈判和交易的成功或失败、法律、社会和经济风险,以及现有现金资源的充足性所带来的风险。 可能导致公司实际结果与前瞻性声明之间存在差异或造成差异的其他因素包括但不限于,那些在公司提交给美国证券交易委员会的备案文件中讨论的风险。 读者应注意,公司的实际结果(包括但不限于公司的Dario商业和监管计划的时间安排和结果如本处所述)可能会与前瞻性声明中所列明的显著不同。 除非适用法律要求,否则公司不承担公开更新任何前瞻性声明的义务,使之与新信息、未来事件或其他情况相符。
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
[email protected]
+1-312-593-4280
dariohealth公司联系方式
Mary Mooney
市场副总裁
[email protected]
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
[email protected]
+315-378-6922
dariohealth投资者关系联系方式
Kat Parrella
投资者关系经理。
[email protected]
+315-378-6922
Logo:
徽标:
SOURCE DarioHealth Corp.
dariohealth公司